ADA Scientific Sessions 2026 Abstract · Jun 5, 2026

Real-World Effectiveness of Novel Antidiabetic Medications on Cardiovascular Outcomes among Medicare Beneficiaries by Race

By FAN W, DAI J, SHI Y et al.

Introduction and Objective: Although clinical trials have demonstrated cardiovascular benefits of newer glucose-lowering agents, their real-world effectiveness for cardiovascular disease (CVD) prevention in older adults, and potential heterogeneity across racial groups, remain uncertain. Methods: We conducted a retrospective cohort study of Medicare beneficiaries aged ≥65 years with type 2 diabetes (T2D) from 21 U.S. states who were enrolled in Medicare Parts A, B, and D from 2014 to 2019, with follow-up through 2022. The study included a 100% sample of American Indian/Alaska Native (AI/AN) beneficiaries and a 20% random sample of other racial groups. Treatment cohorts included initiators of SGLT2i, GLP1-RAs, or other 2nd-line antidiabetic therapies, regardless of metformin use. Incident CVD outcomes, including acute myocardial infarction, ischemic heart disease, heart failure, and stroke/TIA, were identified using ICD9/10 codes. Cox proportional hazards models with propensity score weighting estimated hazard ratios (HRs) for incident CVD associated with SGLT2i and GLP1-RA use compared with other therapies, stratified by race. Results: Among 616,297 adults (mean age 67.6±10.1 years; 49.6% female), 5.1% were AI/AN, 5.6% Asian, 11.4% Black, 18.9% Hispanic, 56.3% White, and 2.7% others. Overall, 47,847, 45,735, 573,309 initiated SGLT2i, GLP1-RAs, and other 2nd-line therapies, respectively. Compared with other agents, SGLT2i use was associated with a 20% lower CVD risk (HR 0.80, 95% CI: 0.79-0.81) and GLP1-RAs a 15% lower CVD risk (HR 0.85, 95% CI: 0.83-0.86). SGLT2i and GLP1-RAs showed stronger CVD risk reduction among Hispanic (30% and 35%), AI/AN (35% and 29%), and Black (32% and 27%) adults than that among their White counterparts. Conclusion: In older adults with T2D, SGLT2i and GLP1-RAs were associated with significantly reduced CVD risk compared to other 2nd-line therapies, particularly among racial minority groups, highlighting their potential to reduce CVD burden and disparities in the real-world settings. Disclosure: W. Fan: None. J. Dai: None. Y. Shi: None. J. OConnell: None. S.M. Manson: None. L. Jiang: None. Funding: American Diabetes Association (CDTR-21)

doi.org/10.2337/db26-2200-pInterventions

AgingResearch.News